24/7 Customer Support

North America Stem Cell Umbilical Cord Blood Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2031

North America Stem Cell Umbilical Cord Blood Market: By Therapeutics (Cancer, Diabetes, Blood Diseases, Immune Disorders, Metabolic Disorders, Bone Marrow Failure Syndrome and Other Diseases); Applications (Transplant Medicine, Regenerative Medicine and Hematopoietic Stem Cell Therapy); and By Country)—Industry Dynamics, Market Size and Opportunity Forecast till 2031

  • Published Date: 17-Apr-2023  |   Format: pdfpowerpointexcel  |  Report ID: AA0422200
    Delivery: 2 to 4 Hours


Stem cell therapy is one of the types of therapies that are being introduced for the betterment and advancement of healthcare sector and people around the world are turning to them and rejecting traditional regimens of drugs and hospital visits.

Stem cell therapy is an expensive therapy as stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. Additionally, there are very few sources for stem cells, labs that are equipped to process stem cells and reputable clinics that provide the treatments.

The North America stem cell umbilical cord blood market is studied from 2018-2031. 

The different segmentations of the North America stem cell umbilical cord blood market are therapeutics, applications and country. 

The adoption of artificial intelligence and data science provides a lucrative growth opportunity in the North America stem cell umbilical cord blood market.

The U.S. held the major share in terms of revenue, in the North America stem cell umbilical cord blood market in 2022. 

The growth rate of the North America stem cell umbilical cord blood market is 16.5%, with an estimated value of US$ 7,051.96 Million by 2031. 

Factors such as increasing demand of genetic testing, fertility and reproduction assisted services and rise in spending capacity and suitable payment plans drives the growth in the North America stem cell umbilical cord blood market during forecast period. 

Legal and ethical issues during collections is a restraining factor which inhibits the growth of the market during the forecast period.

The immune disorders segment is anticipated to grow at the highest CAGR during the forecast period owing to high prevalence of inherited immune system disorders in North America.

Cord blood has huge potential to treat chronic diseases such as cancer, diabetes, blood and immune diseases. Also, it has been extensively used for treatment of genetic diseases. 

The key players operating in the market include Advanced Cell Technology, Inc., Americord Registry LLC, Athersys, Inc., California Stem Cell (CSC), CBR Systems, Inc., LifeCell International Pvt. Ltd., MEDIPOST, Magenta Therapeutics, Mesoblast Ltd, Cryo-Save, Opexa Therapeutics, Inc.,   Regrow Biosciences Pvt Ltd.,   Smart Cells International Ltd., Tacitus Therapeutics, Sino Biological and Teva Pharmaceuticals among others.